On-Demand Webinars

For biopharma leaders, BD&L is more than a pathway to pipeline growth—it’s a series of billion-dollar decisions in a high-risk, fast-changing market. Yet history shows even promising science doesn’t guarantee commercial success.

Using Real World Data to Guide Precision Oncology Drug Development The role of real world data (RWD) & analytics: as new sources of clinico-genomic data and new methods (e.g., natural language processing [NLP], artificial intelligence [AI]) are emerging at rapid pace, can the use of real world evidence (RWE) be optimized to close gaps in target identification/biomarker discovery, indication prioritization, and disease & market understanding?  Strategic challenges in precision oncology: what are the barriers to mapping disease pathways and profiling possible patient targets? Where do investors need reassurance that a development program isn’t just a shot-in-the-dark but rather a well-informed drug targeting endeavour that addresses a true and significant unmet need? Approaches for navigating these uncertainties: how should drug developers balance scientific rigor vs. costs to get the inputs needed to effectively guide development efforts? When is a 4/10 vs. a 9/10 answer acceptable?

The need for more agile and focused research insights comes against a backdrop of increasing pressure across the industry. Staying ahead of the curve not only requires a deep understanding of the intricate interplay of market trends, competitive landscape, and patient needs, but the ability to adapt quickly to new scenarios. At Lumanity, we continuously challenge ourselves on how we can get closer to patients, and to the needs of all stakeholders in ways that deliver incremental value our clients. Lumanity experts will share the most client-relevant insights from four of the papers showcased as part of our recent internal Research Festival.